In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actavis Group agrees to revised management takeover bid

Executive Summary

Actavis Group chairman Bjorgolfur Thor Bjorgolfsson's UK investment company Novator is buying the part of the Icelandic generics firm it doesn't already own for €3.3bn ($4.5bn) in cash, paying €0.98 per each outstanding class A common share (about an 8% premium). Novator already held about 38.5% of Actavis's total class A common shares.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Buy-out
    • Full Acquisition
    • Payment Includes Cash

Related Companies